Preview Mode Links will not work in preview mode

Sep 4, 2019

Multiple Myeloma Update — Part 1: Our interview with Dr Rajkumar highlights the following topics as well as cases from his practice:

  • Updated risk-stratification model for smoldering multiple myeloma (MM) incorporating the revised International Myeloma Working Group diagnostic criteria; therapeutic approach for standard- versus high-risk smoldering MM (00:00)
  • Subcutaneous versus intravenous daratumumab administration for MM (05:28)
  • Efficacy and tolerability of the recently FDA-approved regimen of daratumumab in combination with lenalidomide and dexamethasone for patients with previously untreated MM not eligible for autologous stem cell transplantation (ASCT) (06:52)
  • Activity, tolerability and ongoing trials of carfilzomib- and bortezomib-based triplet regimens for newly diagnosed MM (08:55)
  • Results of the Phase III CASSIOPEIA study: Bortezomib/thalidomide/dexamethasone with or without daratumumab for patients with newly diagnosed MM eligible for ASCT (12:39)
  • Case: A man in his early 80s with MM initially treated with lenalidomide/bortezomib/dexamethasone and maintenance lenalidomide experiences relapse 2 years later (15:02)
  • Benefits and risks of the Bcl-2 inhibitor venetoclax in combination with bortezomib/dexamethasone for relapsed/refractory (R/R) MM with and without the t(11;14) translocation on the Phase III BELLINI trial (16:43)
  • Proposed mechanism of venetoclax-associated mortality in MM (19:35)
  • Understanding the clinical role and limitations of surrogate endpoints for overall survival (24:29)
  • Perspective on the possible design flaws in the BELLINI trial (28:08)

CME information and select publications